Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins

Autores
Pavan, Tycha Bianca Sabaini; Leony, Leonardo Maia; Vieira de Souza, Wayner; Ferreira Santos, Emily; Tavares Daltro, Ramona; Erdens Maron Freitas, Natália; Carvalho Medrado Vasconcelos, Larissa; Lopes Habib, Fernanda; Oliveira Silva, Ângelo Antônio; Fiorani Celedon, Paola Alejandra; Dias Sampaio, Daniel; Tonin Zanchin, Nilson Ivo; Longhi, Silvia Andrea; Neves Santos, Fred Luciano
Año de publicación
2024
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Chagas disease (CD) is a neglected disease caused by Trypanosoma cruzi Chagas, 1909. Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox. There are some gaps that hinder progress in eradicating the disease. There is no test that can efficiently assess cure control after treatment. Currently, the decline in anti-T. cruzi antibody titres is assessed with conventional serological tests, which can take years. However, the search for new markers of cure must continue to fill this gap. The present study aimed to evaluate the decline in serological titres using chimeric proteins after treatment with benznidazole in chronic patients diagnosed with CD. It was a prospective cross-sectional cohort study between 2000 and 2004 of T. cruzi-positive participants from the Añatuya region (Argentina) treated with benznidazole. Serum samples from ten patients were collected before treatment (day zero) and after the end of treatment (2, 3, 6, 12, 24 and 36 months). For the detection of anti-T. cruzi antibodies, an indirect ELISA was performed using two chimeric recombinant proteins (IBMP-8.1 and IBMP-8.4) as antigens. The changes in reactivity index within the groups before and after treatment were evaluated using the Friedman test. All participants experienced a decrease in serological titres after treatment with benznidazole, especially IBMP-8.1. However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.
Fil: Pavan, Tycha Bianca Sabaini. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Leony, Leonardo Maia. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Vieira de Souza, Wayner. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Ferreira Santos, Emily. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Tavares Daltro, Ramona. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Erdens Maron Freitas, Natália. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Carvalho Medrado Vasconcelos, Larissa. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Lopes Habib, Fernanda. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Oliveira Silva, Ângelo Antônio. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Fiorani Celedon, Paola Alejandra. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Dias Sampaio, Daniel. Municipal Health Department of Tremedal, Bahia. Department Brazil's Family Health Strategy; Brasil
Fil: Tonin Zanchin, Nilson Ivo. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Longhi, Silvia Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Fil: Neves Santos, Fred Luciano. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Materia
TRYPANOSOMA CRUZI
CHAGAS
TREATMENT
BIOMARKERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/233625
Acceder
id CONICETDig_959d8fe6f4c95ec0570c026a747fac2f
oai_identifier_str oai:ri.conicet.gov.ar:11336/233625
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteinsPavan, Tycha Bianca SabainiLeony, Leonardo MaiaVieira de Souza, WaynerFerreira Santos, EmilyTavares Daltro, RamonaErdens Maron Freitas, NatáliaCarvalho Medrado Vasconcelos, LarissaLopes Habib, FernandaOliveira Silva, Ângelo AntônioFiorani Celedon, Paola AlejandraDias Sampaio, DanielTonin Zanchin, Nilson IvoLonghi, Silvia AndreaNeves Santos, Fred LucianoTRYPANOSOMA CRUZICHAGASTREATMENTBIOMARKERShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Chagas disease (CD) is a neglected disease caused by Trypanosoma cruzi Chagas, 1909. Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox. There are some gaps that hinder progress in eradicating the disease. There is no test that can efficiently assess cure control after treatment. Currently, the decline in anti-T. cruzi antibody titres is assessed with conventional serological tests, which can take years. However, the search for new markers of cure must continue to fill this gap. The present study aimed to evaluate the decline in serological titres using chimeric proteins after treatment with benznidazole in chronic patients diagnosed with CD. It was a prospective cross-sectional cohort study between 2000 and 2004 of T. cruzi-positive participants from the Añatuya region (Argentina) treated with benznidazole. Serum samples from ten patients were collected before treatment (day zero) and after the end of treatment (2, 3, 6, 12, 24 and 36 months). For the detection of anti-T. cruzi antibodies, an indirect ELISA was performed using two chimeric recombinant proteins (IBMP-8.1 and IBMP-8.4) as antigens. The changes in reactivity index within the groups before and after treatment were evaluated using the Friedman test. All participants experienced a decrease in serological titres after treatment with benznidazole, especially IBMP-8.1. However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.Fil: Pavan, Tycha Bianca Sabaini. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Leony, Leonardo Maia. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Vieira de Souza, Wayner. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Ferreira Santos, Emily. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Tavares Daltro, Ramona. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Erdens Maron Freitas, Natália. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Carvalho Medrado Vasconcelos, Larissa. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Lopes Habib, Fernanda. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Oliveira Silva, Ângelo Antônio. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Fiorani Celedon, Paola Alejandra. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Dias Sampaio, Daniel. Municipal Health Department of Tremedal, Bahia. Department Brazil's Family Health Strategy; BrasilFil: Tonin Zanchin, Nilson Ivo. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Fil: Longhi, Silvia Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Neves Santos, Fred Luciano. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;Czech Academy of Sciences2024-03-20info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/233625Pavan, Tycha Bianca Sabaini; Leony, Leonardo Maia; Vieira de Souza, Wayner; Ferreira Santos, Emily; Tavares Daltro, Ramona; et al.; Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins; Czech Academy of Sciences; Folia Parasitologica; 71; 4; 20-3-2024; 1-90015-56831803-6465CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://folia.paru.cas.cz/doi/10.14411/fp.2024.004.htmlinfo:eu-repo/semantics/altIdentifier/doi/10.14411/fp.2024.004info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:58:33Zoai:ri.conicet.gov.ar:11336/233625instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:58:33.325CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
title Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
spellingShingle Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
Pavan, Tycha Bianca Sabaini
TRYPANOSOMA CRUZI
CHAGAS
TREATMENT
BIOMARKERS
title_short Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
title_full Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
title_fullStr Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
title_full_unstemmed Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
title_sort Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins
dc.creator.none.fl_str_mv Pavan, Tycha Bianca Sabaini
Leony, Leonardo Maia
Vieira de Souza, Wayner
Ferreira Santos, Emily
Tavares Daltro, Ramona
Erdens Maron Freitas, Natália
Carvalho Medrado Vasconcelos, Larissa
Lopes Habib, Fernanda
Oliveira Silva, Ângelo Antônio
Fiorani Celedon, Paola Alejandra
Dias Sampaio, Daniel
Tonin Zanchin, Nilson Ivo
Longhi, Silvia Andrea
Neves Santos, Fred Luciano
author Pavan, Tycha Bianca Sabaini
author_facet Pavan, Tycha Bianca Sabaini
Leony, Leonardo Maia
Vieira de Souza, Wayner
Ferreira Santos, Emily
Tavares Daltro, Ramona
Erdens Maron Freitas, Natália
Carvalho Medrado Vasconcelos, Larissa
Lopes Habib, Fernanda
Oliveira Silva, Ângelo Antônio
Fiorani Celedon, Paola Alejandra
Dias Sampaio, Daniel
Tonin Zanchin, Nilson Ivo
Longhi, Silvia Andrea
Neves Santos, Fred Luciano
author_role author
author2 Leony, Leonardo Maia
Vieira de Souza, Wayner
Ferreira Santos, Emily
Tavares Daltro, Ramona
Erdens Maron Freitas, Natália
Carvalho Medrado Vasconcelos, Larissa
Lopes Habib, Fernanda
Oliveira Silva, Ângelo Antônio
Fiorani Celedon, Paola Alejandra
Dias Sampaio, Daniel
Tonin Zanchin, Nilson Ivo
Longhi, Silvia Andrea
Neves Santos, Fred Luciano
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv TRYPANOSOMA CRUZI
CHAGAS
TREATMENT
BIOMARKERS
topic TRYPANOSOMA CRUZI
CHAGAS
TREATMENT
BIOMARKERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Chagas disease (CD) is a neglected disease caused by Trypanosoma cruzi Chagas, 1909. Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox. There are some gaps that hinder progress in eradicating the disease. There is no test that can efficiently assess cure control after treatment. Currently, the decline in anti-T. cruzi antibody titres is assessed with conventional serological tests, which can take years. However, the search for new markers of cure must continue to fill this gap. The present study aimed to evaluate the decline in serological titres using chimeric proteins after treatment with benznidazole in chronic patients diagnosed with CD. It was a prospective cross-sectional cohort study between 2000 and 2004 of T. cruzi-positive participants from the Añatuya region (Argentina) treated with benznidazole. Serum samples from ten patients were collected before treatment (day zero) and after the end of treatment (2, 3, 6, 12, 24 and 36 months). For the detection of anti-T. cruzi antibodies, an indirect ELISA was performed using two chimeric recombinant proteins (IBMP-8.1 and IBMP-8.4) as antigens. The changes in reactivity index within the groups before and after treatment were evaluated using the Friedman test. All participants experienced a decrease in serological titres after treatment with benznidazole, especially IBMP-8.1. However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.
Fil: Pavan, Tycha Bianca Sabaini. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Leony, Leonardo Maia. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Vieira de Souza, Wayner. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Ferreira Santos, Emily. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Tavares Daltro, Ramona. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Erdens Maron Freitas, Natália. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Carvalho Medrado Vasconcelos, Larissa. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Lopes Habib, Fernanda. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Oliveira Silva, Ângelo Antônio. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Fiorani Celedon, Paola Alejandra. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Dias Sampaio, Daniel. Municipal Health Department of Tremedal, Bahia. Department Brazil's Family Health Strategy; Brasil
Fil: Tonin Zanchin, Nilson Ivo. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
Fil: Longhi, Silvia Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina
Fil: Neves Santos, Fred Luciano. Ministerio de Salud de Brasil. Fundación Oswaldo Cruz. Instituto Oswaldo Cruz;
description Chagas disease (CD) is a neglected disease caused by Trypanosoma cruzi Chagas, 1909. Causative treatment can be achieved with two drugs: benznidazole or Nifurtimox. There are some gaps that hinder progress in eradicating the disease. There is no test that can efficiently assess cure control after treatment. Currently, the decline in anti-T. cruzi antibody titres is assessed with conventional serological tests, which can take years. However, the search for new markers of cure must continue to fill this gap. The present study aimed to evaluate the decline in serological titres using chimeric proteins after treatment with benznidazole in chronic patients diagnosed with CD. It was a prospective cross-sectional cohort study between 2000 and 2004 of T. cruzi-positive participants from the Añatuya region (Argentina) treated with benznidazole. Serum samples from ten patients were collected before treatment (day zero) and after the end of treatment (2, 3, 6, 12, 24 and 36 months). For the detection of anti-T. cruzi antibodies, an indirect ELISA was performed using two chimeric recombinant proteins (IBMP-8.1 and IBMP-8.4) as antigens. The changes in reactivity index within the groups before and after treatment were evaluated using the Friedman test. All participants experienced a decrease in serological titres after treatment with benznidazole, especially IBMP-8.1. However, due to the small number of samples and the short follow-up period, it is premature to conclude that this molecule serves as a criterion for sustained cure. Further studies are needed to validate tests based on these or other biomarkers to demonstrate parasitological cure.
publishDate 2024
dc.date.none.fl_str_mv 2024-03-20
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/233625
Pavan, Tycha Bianca Sabaini; Leony, Leonardo Maia; Vieira de Souza, Wayner; Ferreira Santos, Emily; Tavares Daltro, Ramona; et al.; Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins; Czech Academy of Sciences; Folia Parasitologica; 71; 4; 20-3-2024; 1-9
0015-5683
1803-6465
CONICET Digital
CONICET
url http://hdl.handle.net/11336/233625
identifier_str_mv Pavan, Tycha Bianca Sabaini; Leony, Leonardo Maia; Vieira de Souza, Wayner; Ferreira Santos, Emily; Tavares Daltro, Ramona; et al.; Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins; Czech Academy of Sciences; Folia Parasitologica; 71; 4; 20-3-2024; 1-9
0015-5683
1803-6465
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/http://folia.paru.cas.cz/doi/10.14411/fp.2024.004.html
info:eu-repo/semantics/altIdentifier/doi/10.14411/fp.2024.004
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Czech Academy of Sciences
publisher.none.fl_str_mv Czech Academy of Sciences
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269526970859520
score 13.13397

Publicaciones similares